Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Search Results for "CT P6 Celltrion"

10:32 EDT 19th April 2014 | BioPortfolio

Matching Channels


Matching News

A second lawsuit tests the BPCIA biosimilars ‘patent dance’ waters

By Kurt R. Karst –        Earlier this week, Celltrion Healthcare Co., Ltd. and Celltrion, Inc. (collectively “Celltrion”) filed a Complaint for Declaratory Judgment in the U.S. District...

Celltrion up on takeout rumors

Celltrion Inc. (KOSDAQ:068270) gained W4,100 to W47,400 on Wednesday on rumors in South Korean media outlets that multiple companies were engaged in talks to acquire the Korean biosimilar play. Roche...

Who Will Buy Celltrion?

As you no doubt know, Celltrion, the big Korean CMO, is up for sale. It's biggest investor Chairman Seo Jung Jin wants to part with his $1.3 B stake in the company and is actively seeking buyers. Fier...

Roche, AZ, Teva in the running for Celltrion?

Speculation is swirling around Celltrion again, this time regarding a possible acquisition of the South Korean biosimilars company by a major foreign pharma firm, despite continuing controversy surrou...

Korea’s Celltrion Mum About CEO Travel Ban

Signaling a probe is imminent, local media reported that state prosecutors have banned Celltrion’s CEO from leaving Korea over alleged stock manipulation.

Korea’s Celltrion Dismisses As Rumor Reports That AstraZeneca, Roche And Teva Are Interested Buyers

Celltrion reveals little about the progress of Chairman Seo Jung-jin’s share sell-off as the company’s clinical development moves forward on a Rituxan biosimilar.

Korea’s Celltrion Advances Its First Novel Therapy, Universal Influenza Treatment

Beyond its main focus of biosimilars, Celltrion is pursuing an influenza therapy that would be its first original product.

Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade

Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.

Matching PubMed Articles


Search Whole site using Google

Search BioPortfolio:
Advertisement Advertisement